Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
Osteoporosis Market Forecast
Market Study
Published: June 2010
Pages: For full details, please email keithw@cmsinfo.com
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 10133.33 Buy Now!
Research from: Datamonitor
Sector: Indication Areas
Globally, the osteoporosis market displayed a 3.5% compound annual growth rate (CAGR) between 2005–09, reaching $9.4 billion in 2009. However, the launch of generic alendronate in the majority of markets resulted in a temporary decline in sales during 2009. The market will stabilize during the next 5 years due to generic incursion and then resume growth from 2015 as new drugs are launched.
Introduction
Globally, the osteoporosis market displayed a 3.5% compound annual growth rate (CAGR) between 2005–09, reaching $9.4 billion in 2009. However, the launch of generic alendronate in the majority of markets resulted in a temporary decline in sales during 2009. The market will stabilize during the next 5 years due to generic incursion and then resume growth from 2015 as new drugs are launched.
Reasons to Purchase
-Understand historical (2005–09) and future (2010–19) osteoporosis drug market dynamics and competitive environment.
-Gain insight into the main opportunities and threats specific to the osteoporosis market.
-Evaluate the sales forecasts of marketed, generic, and key pipeline drugs to 2019 in the US, Japan, France, Germany, Italy, Spain, and the UK.
Globally, the osteoporosis market displayed a 3.5% compound annual growth rate (CAGR) between 2005–09, reaching $9.4 billion in 2009. However, the launch of generic alendronate in the majority of markets resulted in a temporary decline in sales during 2009. The market will stabilize during the next 5 years due to generic incursion and then resume growth from 2015 as new drugs are launched.
Reasons to Purchase
-Understand historical (2005–09) and future (2010–19) osteoporosis drug market dynamics and competitive environment.
-Gain insight into the main opportunities and threats specific to the osteoporosis market.
-Evaluate the sales forecasts of marketed, generic, and key pipeline drugs to 2019 in the US, Japan, France, Germany, Italy, Spain, and the UK.